Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
NHLBI Catalyze program supports early-stage medical device prototype optimization and translational research for heart, lung, blood, and sleep (HLBS) diseases.
Funder: National Institutes of Health
Due Dates: June 18, 2025 (New/Renewal/Resubmission/Revision) | August 21, 2025 (AIDS) | October 21, 2025 (New/Renewal/Resubmission/Revision) | December 22, 2025 (AIDS) | February 11, 2026 (New/Renewal/Resubmission/Revision) | April 21, 2026 (AIDS) | June 18, 2026 (New/Renewal/Resubmission/Revision) | August 21, 2026 (AIDS) | October 21, 2026 (New/Renewal/Resubmission/Revision) | December 23, 2026 (AIDS) | February 11, 2027 (New/Renewal/Resubmission/Revision) | April 23, 2027 (AIDS) | June 17, 2027 (New/Renewal/Resubmission/Revision) | August 23, 2027 (AIDS) | October 21, 2027 (New/Renewal/Resubmission/Revision) | December 23, 2027 (AIDS)
Funding Amounts: Up to $300,000 direct costs per year for up to 2 years; minimum 0.25:1 non-federal cost match required.
Summary: Supports optimization and validation of medical device prototypes, diagnostics, and research tools for heart, lung, blood, and sleep (HLBS) diseases; clinical trials are not allowed.
Key Information: Requires a letter of support from an Accelerator Partner and a cost-matching commitment; applications without these will not be reviewed.
Description
This opportunity, offered by the National Heart, Lung, and Blood Institute (NHLBI) under the NIH Catalyze program, funds the optimization and validation of medical device prototypes, diagnostic assays, and research tools targeting heart, lung, blood, and sleep (HLBS) diseases. The program is designed to help transition basic science discoveries into viable products ready for preclinical in vivo testing, with the goal of advancing them toward human use. The initiative emphasizes translational research, product development, and the development of researchers with expertise in entrepreneurship and regulatory strategy.
Projects must focus on late-stage prototype optimization, assay development, or research tool improvement, and are expected to provide a clear path toward preclinical testing. Clinical trials are not permitted under this funding opportunity.
